AlphAIAlphAI — Financial news for AI agents
stocktitan.netAUG 191 min read$VNDA

Millennium reports 3.38M-share passive stake in Vanda (NASDAQ: VNDA)

Millennium Management LLC and related entities report a 5.6% passive stake in Vanda Pharmaceuticals (VNDA), owning 3.38M shares. They share voting and disposal power but deny sole beneficial ownership. The filing is made under a joint agreement.

Original reporting
stocktitan.net
Published Aug 19, 2026, 10:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$VNDA
Neutral
high confidence
Mentioned
$VNDA
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$VNDANeutralLow
01

Why it matters

The filing confirms Millennium Management's passive position in VNDA without control implications.

02

Market read

Routine ownership disclosure with low trading relevance.

03

What to watch

Potential future activist moves if stake increases.

Relevance 4/10Novelty 3/10Timing: reported now

Background

13G filings disclose passive ownership stakes of institutional investors.

Company-level read

Ticker impact

$VNDANeutralHigh confidence
Context

13G filing shows Millennium Management and related entities own 5.6% of Vanda Pharmaceuticals (VNDA).

Expected impact

Likely negligible effect on VNDA price.

Evidence & confidence

Stake size is modest and typical for institutional investors; no change in control or voting power.

Market effects

Sector

No significant impact on the biotech sector.

Regional

Limited to US market participants.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

Stake could signal future interest, but no immediate catalyst.

Key entities

  • Company
    Vanda Pharmaceuticals Inc.

    Biopharmaceutical company (NASDAQ: VNDA).

  • Investor
    Millennium Management LLC

    Institutional investor reporting a 5.6% stake.

Read at source← All news

Related articles

SEP 29
$VNDAHighAI 9/10

Why is Vanda Pharmaceuticals stock surging today?

Vanda Pharmaceuticals (VNDA) stock rose 12% in after-hours trading to $5.63 after reporting positive phase III results for its Hetlioz treatment in delayed sleep-wake phase disorder. The trial met its primary endpoint, and the company plans to discuss the data with the FDA. If approved, Hetlioz would be the first FDA-approved medicine for this condition.

investing.com2 min
SEP 11
$VNDAMedAI 8/10

VNDA: BYSANTI and NEREUS launches, plus pipeline catalysts, set the stage for major revenue growth

Vanda Pharmaceuticals Inc. [VNDA] launched two new drugs, NEREUS and BYSANTI. BYSANTI's launch and a switch strategy from Fanapt are expected to drive near-term revenue. The company aims for $750 million in psychiatry revenue by 2030, supported by phase III readouts and product diversification, according to its 12th Annual Cantor Fitzgerald Global Healthcare Conference.

tradingview.com1 min
AUG 24
$VNDAMedAI 8/10

Vanda receives EU orphan designation for imsidolimab GPP treatment

Vanda Pharmaceuticals (VNDA) received EU orphan designation for imsidolimab, a potential treatment for generalized pustular psoriasis, following a positive opinion from the EMA. The designation, the first for a GPP treatment in the EU, may provide regulatory and market benefits. The company's Biologics License Application for imsidolimab is under FDA review with a target action date of December 12, 2026.

grafa.com1 min
AUG 24
$VNDAMed

Vanda Wins First EU Orphan Designation For Imsidolimab In Generalized Pustular Psoriasis; Stock Up

Vanda Pharmaceuticals (VNDA) received EU Orphan Drug Designation for Imsidolimab to treat generalized pustular psoriasis. The designation, granted by the European Commission, follows a positive opinion from the EMA. Imsidolimab targets the IL-36 signaling pathway. VNDA's stock rose 6.06% in pre-market trading. The FDA is reviewing the drug's BLA with a target action date of December 12, 2026.

rttnews.com2 min